Oncocuetics, Inc. (Oncoceutics)

Oncology Corporate Profile

HQ Location

3624 Market Street
University City Science Center, Suite 5E
Philadelphia, PA 19104

Company Description

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies.

Website: http://oncoceutics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ONC 201DRD2 antagonistGlioblastoma Multiforme (GBM)II
ONC 201DRD2 antagonistMultiple MyelomaII
ONC 201DRD2 antagonistNeuroendocrine tumorII
ONC 201DRD2 antagonistAcute Myelogenous Leukemia (AML)I
ONC 201 (+ dexamethasone)DRD2 antagonistMultiple MyelomaI
ONC 201DRD2 antagonistNon-Hodgkin's Lymphoma (NHL)I
ONC 201DRD2 antagonistVarious cancer typesI
ONC 212Various cancer typesPreclinical
ONC 206Various cancer typesPreclinical

View additional information on product candidates here »

Source: http://oncoceutics.com/

Recent News Headlines

There are no news items to display